

AD _____

Award Number: W81XWH-05-1-0611

TITLE: Effects of Modifications in the Laminin-10 Basal Laminina on Prostate Cancer Invasion

PRINCIPAL INVESTIGATOR: Sangita C. Pawar Ph.D.
Elisabeth L. Bair Ph.D

CONTRACTING ORGANIZATION: University of Arizona
Tucson AZ 85722

REPORT DATE: October 2006

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 01-10-2006		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 1 Oct 2005 - 30 Sep 2006	
4. TITLE AND SUBTITLE Effects of Modifications in the Laminin-10 Basal Laminina on Prostate Cancer Invasion				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-05-1-0611	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Sangita C. Pawar Ph.D.; Elisabeth L. Bair Ph.D. E-Mail: spawar@azcc.arizona.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Arizona Tucson AZ 85722				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES-Original contains colored plates: ALL DTIC reproductions will be in black and white.					
14. ABSTRACTIn order for prostate cancer to metastasize, it must invade through a laminin-511 rich barrier. We have previously shown that the matrix metalloprotease, MT1-MMP, which is expressed in prostate cancer but not in normal prostate tissue, cleaves the laminin alpha-5 chain into four distinct fragments. This cleavage allows for increased prostate cancer cell migration in vitro. Laminin-511 cleavage also occurs in vivo in human prostate tissue. Cleavage of laminin-511 and release of laminin-511 fragments leads to altered cell function leading to increased cell migration and invasion in in vitro assays. We have demonstrated that prostate cancer cells treated with laminin-511 that has been cleaved by MT1-MMP have increased EGFR phosphorylation compared with cells grown on tissue culture plastic or intact laminin-511 in a Western blot. We have purified a recombinant 45kDa laminin-511 N-terminal cleavage fragment, which contains laminin EGF-like domains. Treatment of prostate cancer cells with soluble recombinant fragment demonstrates that the cleaved laminin fragment acts as a matrikine, activating the EGFR on prostate cancer cells in a Western blot. This work demonstrates that increased MT1-MMP expression in prostate cancer not only cleaves the major laminin surrounding prostate cancer to clear a path for migration, but also releases active fragments from the laminin-511 that signal for increased migration.					
15. SUBJECT TERMS Prostate cancer, laminin-10, MT1-MMP					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	14	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	5
Key Research Accomplishments.....	8
Reportable Outcomes.....	8
Conclusion.....	8
References.....	8
Appendices.....	10

Introduction

Prostate cancer is currently the most commonly diagnosed neoplasm and the second leading cause of cancer deaths in men in the United States. Due to the aging population, prostate cancer incidence and mortality is expected to increase. Thus, improvements in prevention, early diagnoses, and treatment are needed [1]. Hopefully, understanding molecular events of prostate cancer progression will lead to the development of novel therapies for the disease. A prostate cancer's ability to develop an invasive and metastatic phenotype is arguably the most important determinant in the clinical relevance of prostate cancer; and therefore, the study of factors involved in the development of this phenotype is of primary importance. There are at least two recognized phenotypes of prostate cancer. One is a clinically aggressive cancer that can become life-threatening relatively fast, while the other is a slow- growing, "latent" form, which may ever present itself clinically [2].

To date, there is no method to differentiate between these two forms of prostate cancer, leading to potential over- and under- treatment of this disease [3]. For this reason, identification and understanding of molecular alterations during prostate cancer progression is essential to distinguish between cases that will progress rapidly to advanced metastatic cancer and those with little likelihood of progressing. This will hopefully lead to more accurate prognoses and appropriate treatments. In addition, identification of biomarkers will be useful for recognizing individuals with a higher risk for prostate cancer and will allow for earlier detection and better treatment of advanced disease. In particular, there is a growing need for biomarkers that access the tumor microenvironment as predictors of metastases [4].

In order for a cancer to metastasize, it must first invade through the basement membrane that surrounds it, migrate through the stroma, invade blood vessels and travel through the bloodstream to a new location where it extravasates the vessel and begins growing at the new site. The mechanisms by which a cancer is enabled to invade and metastasize are currently under intense study. Interactions of the cell with its environment are thought to play a major role in signaling for these invasive processes to occur. Upregulation of proteolytic enzymes, such as the matrix metalloproteases, is suspected of being involved in the metastatic process.

Remodeling of the extracellular matrix (ECM) through proteolysis of ECM proteins is an important step in the metastatic progression of cancer, allowing for invasion of neoplastic cells through the basal lamina (BL) and into the stroma [5]. Proteolysis creates paths for migration, releases signaling molecules such as growth factors bound in the ECM, and generates biologically active ECM fragments [6-10].

Prostate cancer is surrounded by a BL composed mainly of laminin-10, laminin-2, type IV collagen, and entactin [11]. In order for prostate cancer to invade the stroma and intravasate into the vasculature, it must move through this Ln-10 rich BL either by proteolysis or ameboid movement [12]. Ln-10 ($\alpha 5\beta 1\gamma 1$) has been previously identified as a substrate for cell migration and cell adhesion [13]. It is now known that MT1-MMP can cleave the laminin-10 $\alpha 5$ chain and this cleavage allows for increased prostate cancer cell migration. We have preliminary evidence that the laminin-10 $\alpha 5$ chain protein cannot be detected in perineural invasive prostate cancer by immunohistochemistry (Figure 3). This apparent loss of laminin-10 protein could be due to complete cleavage by MT1-MMP so that antibodies to the $\alpha 5$ chain cannot bind or it could be due to loss of laminin-10 expression in invasive cancer. We propose that modifications in

extracellular matrix proteins surrounding prostate cancer play an important role in the progression of the disease and an understanding in the global changes in cancer that take place as a result of these modifications will be important for future prostate cancer research, treatment, and diagnosis.

Body

Previously, we have demonstrated that the matrix metalloprotease, MT1-MMP, cleaves the laminin-10 alpha 5 chain into four distinct fragments with apparent molecular weights of 45, 160, 190, and 310 kDa. When human prostate cancer cells are plated on cleaved laminin-10, there is an increase in migration on and invasion through the laminin-10 substrate. This work was published in the journal *Neoplasia* in April 2005. We are currently in the process of examining the biologic effects of these fragments, and the potential cleavage of laminin-10 in human prostate cancer.


To test the biologic effects of the laminin-10 cleavage fragments, recombinant proteins corresponding to laminin alpha 5 chain cleavage products are being produced. To date, the 45kDa N-terminal end of the alpha 5 chain has been expressed in E.Coli and purified on a Ni²⁺ column. This protein has been tested to determine whether it is the cause of the biologic effects observed when prostate cancer cells are treated with cleaved laminin-10 (EGFR phosphorylation, proliferation, migration). We have treated DU-145 cells with purified laminin-10 and purified laminin-10 that was treated (cleaved) with MT1-MMP. These experiments demonstrated an increase in EGFR phosphorylation at tyrosine 1068. Purified laminin-10 induced some EGFR activation, but cleaved laminin-10 demonstrated a more robust activation. We have found that treating DU-145 prostate cancer cells with 1μM concentration of the 45kDa fragment induces phosphorylation of the EGF receptor at tyrosine 1068, similarly to treating DU-145 cells with 1μg purified, cleaved laminin-10.

We also have evidence that the extracellular matrix protein, laminin-10, though present in normal prostate and prostate cancer, may be downregulated in perineurally invasive prostate cancer. With current techniques, we do not know whether this apparent lack of protein expression by immunohistochemistry with a laminin-10 alpha 5 chain antibody is due to loss of protein, or clipping of the alpha 5 chain by increased MT1-MMP expression. Since there are currently no antibodies available to the cleaved forms of the alpha 5 chain, we chose to examine mRNA expression of the protein to determine if it is being expressed in perineurally invasive prostate cancer. RNA probes were generated against the human laminin alpha 5 chain and human MT1-MMP. These probes are currently in use using *in situ* hybridization to detect message for these proteins in human prostate cancer tissue. The technique for *in situ* hybridization on human prostate tissues has been worked out, and preliminary experiments with the alpha 5 chain probe indicate that mRNA is present in prostate cancer, though to a lesser extent than mRNA present in normal glands. Perineurally invasive prostate tissue still needs to be examined.

Hypothesis: LM-511 cleavage by MT1-MMP results in decreased adhesion and increased migration of prostate cancer cells due to release of biologically active LM-α5 fragments


containing EGF-like domains that function as matrikines, can bind and activate the EGF receptor.

Activation of EGFR on cells plated on cleaved LM-511.




LM-511 (μg) was coated on a 6-well tissue culture plate and treated with catalytic domain of MT1-MMP (2.1 nmol) or left intact. DU-145 cells were then plated on uncoated and LM-511 coated wells. EGF was added to an uncoated well as a control for activation. 16 hours after plating, cells were lysed and analyzed for EGFR activation at Tyr 1068. Results demonstrate EGFR activation when cells were plated on intact LM-511, with an increase in EGFR activation when cells were plated on cleaved LM-511.

Activation of EGFR with soluble LM-511 fragments.




DU-145 cells were seeded in a 6-well tissue culture plate and stimulated with: EGF, LM-511 fragments produced by incubating intact LM-511 with catalytic domain of MT1-MMP 16 hr, intact LM-511, or were left untreated. Results demonstrate that cleaved LM-511 fragments activate EGFR to a greater extent than intact LM-511, and that the receptor is not activated with no treatment. Lamin A/B protein was used as a loading control.

Structural representation of LM- α 5 chain 45 KD fragment.



The LM- α 5 chain 45 kDa fragment we have produced in E.Coli has been modeled based on its amino acid sequence. The fragment contains a complete EGF-like domain at its C-terminus.

LM- α 5 45 KD fragment activates EGFR.



DU-145 cells were treated with EGF, intact soluble LM-511, cleaved soluble LM-511, 45 kDa soluble fragment, or left untreated. Results indicate that the 45 KD fragment activates EGFR above endogenous levels (untreated). Total EGFR protein is shown as a loading control.

Key Research Accomplishments

1. Trained in recombinant protein design, synthesis, and purification.
2. Trained in in situ hybridization technique.
3. 2005, NCI-sponsored Tumor Microenvironment Training Program: Organotypic Models Training Program in Dr. Isaiah Fidler's laboratory in Houston, TX participant. .
4. Acquired knowledge novel migration and invasion assays. Recombinant 45kDa fragment of laminin alpha5 chain was made and purified.
5. Biochemical assays of EGFR phosphorylation were performed using phospho-specific antibodies.
 - a. EGFR was phosphorylated in when treated with or grown on purified, cleaved laminin-10
 - b. EGFR was phosphorylated after treatment with purified 45KD recombinant laminin alpha5 chain fragment.

Reportable Outcomes

Bair EL, Bowden, GT, Nagle, RB "Cleaved Laminin- $\alpha 5\beta 1\gamma 1$ Fragment Activates EGFR in Prostate Cancer Cells" An AACR Special Conference in Cancer Research "Cancer, Proteases, and the Tumor Microenvironment" November 30-December 4, 2005, Bonita Springs, Florida.

Conclusions

- LM-511 cleaved with MT1-MMP contains potentially bio-active fragments.
- Cleaved LM-511 fragments activate the EGFR at Tyr 1068.
- Recombinant 45 kDa LM- $\alpha 5$ chain demonstrates activity in activating the EGFR.

References

1. Carter, H.B. and D.S. Coffey, *The prostate: an increasing medical problem*. Prostate, 1990. **16**(1): p. 39-48.
2. von Eschenbach, A.C., et al., *Exploration of new pathologic factors in terms of potential for prognostic significance and future applications*. Cancer, 1996. **78**(2): p. 372-5.
3. Hamdy, F.C., *Prognostic and predictive factors in prostate cancer*. Cancer Treat Rev, 2001. **27**(3): p. 143-51.
4. Harding, M.A. and D. Theodorescu, *Prostate tumor progression and prognosis. interplay of tumor and host factors*. 2000. **5**(6): p. 258-264.
5. Noel, A., et al., *Emerging roles for proteinases in cancer*. Invasion Metastasis, 1997. **17**(5): p. 221-39.
6. Foda, H.D. and S. Zucker, *Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis*. Drug Discov Today, 2001. **6**(9): p. 478-482.
7. Kleinman, H.K., et al., *Role of basement membrane in tumor growth and metastasis*. Surg Oncol Clin N Am, 2001. **10**(2): p. 329-38, ix.
8. Simian, M., et al., *The interplay of matrix metalloproteinases, morphogens and growth*

- factors is necessary for branching of mammary epithelial cells.* Development, 2001. **128**(16): p. 3117-31.
9. Stetler-Stevenson, W.G. and A.E. Yu, *Proteases in invasion: matrix metalloproteinases.* Semin Cancer Biol, 2001. **11**(2): p. 143-52.
 10. Egeblad, M. and Z. Werb, *New functions for the matrix metalloproteinases in cancer progression.* Nat Rev Cancer, 2002. **2**(3): p. 161-74.
 11. Nagle, R.B., et al., *Adhesion molecules, extracellular matrix, and proteases in prostate carcinoma.* J Cell Biochem Suppl, 1994. **19**: p. 232-7.
 12. Wolf, K., et al., *Compensation mechanism in tumor cell migration: mesenchymal amoeboid transition after blocking of pericellular proteolysis.* J Cell Biol, 2003. **160**(2): p. 267-77.
 13. Pouliot, N., N.A. Saunders, and P. Kaur, *Laminin 10/11: an alternative adhesive ligand for epidermal keratinocytes with a functional role in promoting proliferation and migration.* Exp Dermatol, 2002. **11**(5): p. 387-97.

Elisabeth L. Bair

University of Arizona
College of Medicine Research Office
1501 N. Campbell Ave., Room 2208
Tucson, Arizona 85724-5016
United States

Phone: (520) 626-3827
Fax: (520) 626-7588
Email: ebair@email.arizona.edu

Education:

B.A., Wittenberg University, Wittenberg University, Biochemistry/Molecular Biology, 2000
Ph.D., University of Arizona, Cancer Biology, 2004

Professional Experience:

2006-present, Research Affairs Specialist, University of Arizona College of Medicine Research Office
2004-2006, University of Arizona, Cancer Center, Postdoctoral Research Associate
2000-2004, Graduate Research Assistant, University of Arizona, Cancer Biology, Arizona Cancer Center
1999-2000, Research Assistant, University of Arizona, Radiation Oncology, Arizona Cancer Center
1999-1999, Undergraduate Biology Research Program, University of Arizona, Radiation Oncology, Arizona Cancer Center
1998-1998, Undergraduate Biology Research Program, University of Arizona, Radiation Oncology, Arizona Cancer Center

Funding Received:

- DOD Postdoctoral Traineeship Award, “Effects of Modifications in the Laminin-10 Basal Lamina on Prostate Cancer Invasion”, \$, from 10/2005 to 10/2007
- Cancer Biology Postdoctoral T-32 Training Grant, National Institutes of Health, University of Arizona, from 6/2005 to 10/2005
- Cancer Biology Predoctoral T-32 Training Grant, National Institutes of Health (NIH), University of Arizona, from 8/2002 to 12/2004

Publications:

- **Bair EL**, Nagle RB. Changing Extracellular Matrix Ligands During Metastasis. In Cress AE and Nagle RB (eds), Cell Adhesion and Cytoskeletal Molecules in Metastasis, Springer Science, Submitted.
- Calaluce R, Beck S, **Bair E**, Pandey R, Greer K, Hoying A, Hoying J, Mount D, Nagle R. Human Laminin-5 and Laminin-10 Mediated Gene Expression of Prostate. Prostate, In Press 2006.
- **Bair EL**, Nagle RB, Ulmer TA, Laferté S, Bowden GT. 90K/Mac-2 Binding Protein Is Expressed in Prostate Cancer and Induces Promatrilysin Expression. The Prostate. 66(3):283-93, 2006.

- **Bair EL**, Chen ML, McDaniel K, Sekiguchi K, Cress AE, Nagle RB, Bowden, GT. Membrane Type 1 Matrix Metalloprotease Cleaves Laminin-10 and Promotes Prostate Cancer Cell Migration. *Neoplasia*. 7(4): 380-9, 2005.
- Udayakumar TS, **Bair EL**, Nagle RB, Bowden GT. Pharmacological Inhibition of FGF Receptor Signaling Inhibits LNCaP Prostate Tumor Growth, Promatrilysin, and PSA Expression. *Molecular Carcinogenesis*. 38(2): 70-7, 2003.
- Udayakumar TS, Chen ML, **Bair EL**, Von Bredow DC, Cress AE, Nagle RB, Bowden GT. Membrane Type-1-matrix Metalloproteinase Expressed By Prostate Carcinoma Cells Cleaves Human Laminin-5 Beta3 Chain and Induces Cell Migration. *Cancer Research*. 63(9): 2292-9, 2003.
- **Bair EL**, Massey CP, Tran NL, Borchers AH, Heimark RL, Cress AE, Bowden GT. Integrin- and Cadherin-mediated Induction of the Matrix Metalloprotease Matrilysin in Cocultures of Malignant Oral Squamous Cell Carcinoma Cells and Dermal Fibroblasts. *Experimental Cell Research*. 270(2): 259-67, 2001.
- DeRoock IB, Pennington ME, Sroka TC, Lam KS, Bowden GT, **Bair EL**, Cress AE. Synthetic Peptides Inhibit Adhesion of Human Tumor Cells to Extracellular Matrix Proteins. *Cancer Research*. 61(8): 3308-13, 2001.

Honors and Awards Information:

- 2005, NCI-sponsored Tumor Microenvironment Training Program: Organotypic Models Training Program in Dr. Isaiah Fidler's laboratory in Houston, TX participant.
- 2005, Young Pathologist Fellowship, American Society for Investigative Pathology (ASIP), University of Arizona
- 2003, Annual Meeting Predoctoral Travel Award, American Society for Cell Biology (ASCB), University of Arizona
- 2000, John and Betty Anderson Memorial Scholarship Endowment, University of Arizona
- 1999, Departmental Honors, Biochemistry/ Molecular Biology, Wittenberg University
- 1997, Saturn/NationsBank Undergraduate Fellowship
- 1996-2000, Wittenberg University Scholar Undergraduate Fellowship

Sangita C. Pawar, Ph.D. 1515 N. Campbell Ave., Rm # 4957, Tucson, AZ, 85724
sangitapawar@gmail.com Phone : 520-270-9036

Date / Place of Birth January 8th, 1972. Mumbai, India
Nationality / Citizenship Indian
Visa Status H1B

Education

Degree/Diploma	Institution	Date
Post Doctoral Fellow	Arizona Cancer Center, University of Arizona, Tucson, AZ, U.S.A.	June 2006-Present
Ph.D. (Molecular and Cellular Biology) Supervisor: Dr. Anne E. Cress	Arizona Cancer Center, University of Arizona, Tucson, AZ, U.S.A.	August 2001-May 2006
M.Sc. (Microbiology)	Bhavans College, Mumbai University, Mumbai, India	June 1999 – May 2001
Diploma in Clinical Analysis	Sophia College, Mumbai, India.	June 1993 – May 1994
B.Sc. (Microbiology)	Sophia College, Mumbai University, Mumbai, India.	June 1990 – May 1993

Teaching Experience

2005: Research supervisor for Tiama Friend undergraduate Minority Health Disparities Summer Research Program, University of Arizona, AZ.
2005: Mentored following students in their research projects: Janice Lopez, Win Win, Kelvin Pond and Sabrina Sykes.
2003: Teaching Assistant for BIOC 411 (Molecular Biology).
2002: Teaching Assistant for MCB 410 (Cell Biology).

Technical Skills

Western Blotting, Immunoprecipitation, Immunocytochemistry, Immunohistochemistry, Flowcytometry, PCR and Cell Culture.

Honors and Awards

2006 Department of Defense Post-doctoral Fellowship Award
2004 Women in Science and Engineering Travel Award.

Poster Presentations

“Integrin $\alpha 6$ cleavage blocked by tetraspanin CD151 interaction”

Sangita C. Pawar, Jaime M.C. Gard, Raymond Nagle, Anne E. Cress.

Membrane Organization by Tetraspanins and Small Multi-Transmembrane Proteins.

FASEB Summer Research Conferences, Tucson, AZ.

July 2006

“Integrin $\alpha 6$ clipping: A novel modification to modulate cell migration” Sangita C.

Pawar, Manolis C. Demetriou, Raymond B. Nagle, G. Tim Bowden and Anne E. Cress.

American Society for Cell Biology, Moscone Center, San Francisco, CA.

December 2005.

“Integrin Clipping: Enhancing osteolytic activity in prostate cancer.” Sangita C. Pawar,

Tamara E. King, Frank Porreca, Raymond B. Nagle, Anne E. Cress.

National Institute of Health, Bethesda, MD.

May 2005

“Integrin $\alpha 6$ clipping: A novel modification to modulate cell migration” Sangita C.

Pawar, Manolis C. Demetriou, Michael E. Pennington, Kevin A. Kwei, Marianne B.

Powell, G. Tim Bowden, and Anne E. Cress.

American Society for Matrix Biology, San Diego, California.

November 2004.

Peer Reviewed Publications

Sangita C. Pawar, Manolis C. Demetriou, Raymond B. Nagle, G. Tim Bowden and

Anne E. Cress. “Integrin $\alpha 6$ clipping: A novel modification to modulate cell migration.”

Exp. Cell Res. 2007 Jan 17

Oshiro MM, Kim CJ, Wozniak RJ, Junk DJ, Munoz-Rodriguez JL, Burr JA, Fitzgerald M, **Pawar SC**, Cress AE, Domann FE, Futscher BW. (2005). Epigenetic silencing of DSC3 is a common event in human breast cancer. *Breast Cancer Res.* 2005;7(5):R669-80.

Abstract Published

Sangita Pawar, Tamara King, Frank Porreca, Ray Nagle, Anne Cress

Integrin clipping: Enhancing osteolytic activity in prostate cancer. *Journal of Bone and Mineral Research.* 2005; 20 (2): P40

Manuscript in preparation

Sangita Pawar, Tamara King, Lisa Majuta, Ray Nagle, Frank Porreca, Anne Cress

“The $\alpha 6$ p variant of the $\alpha 6$ integrin plays a critical role in osteolytic activity and bone-cancer induced nociception in prostate cancer in a murine bone cancer model.”

Sangita C. Pawar and Anne E. Cress. “Integrin $\alpha 6$ cleavage blocked by tetraspanin CD151 interaction”.

References

Dr Anne E. Cress
Professor
Department of Cell Biology and Anatomy
Arizona Cancer Center
Room 4963
1515 North Campbell Avenue
Tucson, AZ, 85724
Phone (520) 626-7553
Fax: (520) 626-4979
E-mail: acress@azcc.arizona.edu

Dr G. Tim Bowden
Professor
Department of Cell Biology and Anatomy
Arizona Cancer Center
Room 4999
1515 North Campbell Avenue
Tucson, AZ, 85724
Phone (520) 626-6006
Fax: (520) 626-4979
E-mail: tbowden@azcc.arizona.edu

Dr Ray B. Nagle
Professor
Department of Pathology
Arizona Cancer Center
Room 3963
1515 North Campbell Avenue
Tucson, AZ, 85724
Phone (520) 520-626-5566
E-mail: rnagle@email.arizona.edu